surpass trial tirzepatide is finally here – what's the big deal? – GP Voice Tirzepatide outcompetes long-acting insulin in

Descubre cmo combatir la flacidez, el estreimiento y la fatiga de los tratamientos GLP-1

If you want to contact us please email [email protected]

We report an unusual case of diabetic ketoalkalosis, a mixed acid-base disorder, in a 57-year-old female patient with insulin-dependent T2DM following a switch to Mounjaro (tirzepatide)

Purpose of Review This review will summarize the most contemporary trials for glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and present guidance on management and recommendations on adjunctive tapering of insulin in patients with insulin-dependent diabetes mellitus, which we term de-insulinization. Recent Findings GLP1-RA and SGLT2-i are the principal classes of diabetes medications evidencing cardiovascular benefit

Just real, doctor-prescribed weight loss tailored to your body

Learn how canagliflozin (Invokana) works, its side effects, dosing, and cardiovascular benefits